Apatinib‐induced Grade 3 hand‐foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. Issue 2 (11th February 2020)

• Record Type: Journal Article
• Authors: Ren, Yue; Li, Ting; Du, Lei‐Ya; Qiu, Ye; Wang, Shan‐Bing; Lei, Kai‐Jian; Jia, Yu‐Ming
• Is Part Of: Dermatologic therapy. Volume 33:Issue 2(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-11
• Subjects: apatinib -- thalidomide -- the hand‐foot syndrome; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.13241
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Hand‐foot syndrome (HFS) is a specific cutaneous toxicity caused by a variety of antitumor drugs. The most common drugs include capecitabine, pegylated liposomal doxorubicin and fluorouracil (PLD), tyrosine kinase inhibitor. It is a dose‐limiting cutaneous toxicity of these drugs. We reported an advanced lung adenocarcinoma female patient, who developed a Grade 3 HFS after a third‐line treatment with apatinib of 250 mg for 10 days, the patient developed intolerable pain with pruritus. Large erythema on the skin of the hand, with local ulceratio, exudation, and desquamation of cutaneous lesions. After treatment with 100 mg of thalidomide every night for 1 week, the patient's HFS was significantly relieved, and the duration of the remission was about 2 months, which not only significantly improved the patient's quality of life, but also maintained the antitumor strength.